Tactile Systems Technology said it reeled in a $10.4 million Series B round led by Radius Ventures, with the proceeds to go toward acquiring "a leading new product" and patents for treating lymphedema, or fluid retention.
"With the new technologies, Tactile Systems will be able to update its solutions and also expand into at-home treatments for patients with other vascular diseases. The acquired technology has 510(k) market clearance and an assigned Medicare reimbursement code," according to a press release.
"This financing will help us advance standard of care in treating chronic diseases at home by providing growth capital for products and technologies in the lymphedema and chronic wound areas to augment our existing line, including the Flexitouch system," CEO Jerry Mattys said in prepared remarks. "These new technologies will allow us to strengthen our core business, fill gaps in our current markets and gain access to new markets."
Galen Partners, which led Tactile Systems’ $11.8 million Series A round in 2007, also participated in the Series B round.
Philips closes $1.6B share buyback
Philips (NYSE:PHG) said it’s completed the share buyback program it began last year, having spent about $1.62 billion repurchasing nearly 82.4 million shares at an average price of €15.03 (about $19.64). PHG shares were trading at $24.39 as of about 10:30 this morning. The company now owns about 3.4% of its own stock.
Read more
EnteroMedics inks $45M stock deal
EnteroMedics (NSDQ:ETRM) inked a deal with Terrapin Opportunity to sell up to $45 million worth of its stock over 2 years as it gears up to unblind its ReCharge study and commercialize its Maestro weight-loss “pacemaker” next year.
Read more
VirtualScopics lowers outlook
VirtualScopics (NSDQ:VSCP) said it expects its 2012 revenues to be between $12.5 million and $13 million, about 10.7%-13.3% lower than its prior guidance, due to customer delays and slower new project awards.
Read more
Novation touts 69% savings on capital equipment
Group purchasing organization Novation is touting its 4th-quarter group buys for capital equipment, saying members can save up to 69% on high-ticket items such as MRI machines and CT machines.
Read more
Baxter hits 52-week high
Shares of Baxter (NYSE:BAX) hit a 52-week high today, reaching $61.95 before subsiding to $61.85 as of about 10:45 this morning.
Analysts’ ups and downs
- Endo Health (NSDQ:ENDP): UBS lowers price target to $45, sets "buy" rating.
